¿¬¼ö°­ÁÂ
Àü³²´ëÇб³º´¿ø Á¦ 123Â÷ È£³²¼øȯ±âÇÐȸ Çмú´ëȸ ¹× ¿¬¼ö°­Á : 2018-12-08
Àü³²´ëÇб³º´¿ø Á¦ 123Â÷ È£³²¼øȯ±âÇÐȸ Çмú´ëȸ ¹× ¿¬¼ö°­Á : 2018-12-08
±³À°ÀÏÀÚ : 2018-12-08
±³À°Àå¼Ò : ¿©¼ö º£³×Ä¡¾Æ È£ÅÚ ÄÁº¥¼ÇȦ  
±³À°ÁÖÁ¦ : Á¦ 123Â÷ È£³²¼øȯ±âÇÐȸ Çмú´ëȸ ¹× ¿¬¼ö°­ÁÂ
ÁÖÃÖ±â°ü : Àü³²´ëÇб³º´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : ½ÉÀå¼¾ÅÍ  
´ã´çÀÚ : ±èº¸Àº
¿¬¶ôó : 062-220-6246  
À̸ÞÀÏ : wsboeun@naver.com      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : Àü¶ó³²µµ
±³À°½Ã°£ : 8 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 0¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 08:50~09:00 °³È¸»ç  ±æ±¤Ã¤(È£³²¼øȯ±âÇÐȸ ȸÀå) 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 09:00~10:20 Session I ½ÉÇ÷°üÁúȯÀÇ ÃֽŠÁö°ß 1: Updated Guidelines  Á¤¸íÈ£, ÁÖÂù¿õ(Àü³²ÀÇ´ë, ÀüºÏÀÇ´ë) 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 09:00~09:15 2018 ESC, 2018 KSH vs. 2017 ACC/AHA Guidelines for the management of arterial hypertension  ±èÁÖÇÑ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 09:15~09:30 2018 ESC Guidelines for cardiovascular disease during pregnancy  ÀÓÁöÇö(ÀüÁÖ¿¹¼öº´¿ø) 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 09:30~09:45 2018 ESC Guidelines on myocardial revascularization  ±è¼ÛÀÌ(Á¦ÁÖÀÇ´ë) 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 09:45~10:00 2018 ACC/AHA Guidelines for the management of adult congenital heart disease  Á¶À翵(Àü³²ÀÇ´ë) 
Åä·Ð 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 10:00~10:20 ÅäÀÇ  ±èÁØ¿ì, ·ùÁ¦¿µ, ¹ÚÇü¿í, ÀÌ»óÀç(¸ñÆ÷Áß¾Óº´¿ø, ÀüÁÖ¿¹¼öº´¿ø, Àü³²ÀÇ´ë, ¿ø±¤ÀÇ´ë) 
È޽Ġ12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 10:20~11:00 Coffee Break & Oral Poster Session  () 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 10:20~11:00 Oral Poster Presentation  ±è°èÈÆ, ±è±â¼®(Àü³²ÀÇ´ë, Á¦ÁÖÀÇ´ë) 
Åä·Ð 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 10:20~11:00 ÅäÀÇ  ±â¿µÀç, ±èÀÎÀç, ¹ÚÇõÁø, ¿À¼º½Ä(Á¶¼±ÀÇ´ë, ±¤ÁÖº¸Èƺ´¿ø, Àü³²ÀÇ´ë, ÀüÁÖ¿¹¼öº´¿ø) 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 11:00~12:20 Session II ½ÉÇ÷°üÁúȯÀÇ ÃֽŠÁö°ß 2  ±æ±¤Ã¤, Á¶Á¤°ü(°¡½¿¶Ù´Â³»°ú, Àü³²ÀÇ´ë) 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 11:00~11:15 Optimal management for AF in patients with HFrEF  À̱âÈ«(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 11:15~11:30 FFR-guided PCI: recent update  ±èÇö±¹(Á¶¼±ÀÇ´ë) 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 11:30~11:45 Management of asymptomatic preexcitation  Á¤·¡¿µ(ÀüºÏÀÇ´ë) 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 11:45~12:00 Chronic total occlusion: PCI or optimal medical treatment  Á¶À翵(¿ø±¤ÀÇ´ë) 
Åä·Ð 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 12:00~12:20 ÅäÀÇ  ±è¼º¼ö, ½ÉµÎ¼±, Á¤¿µ¿í, Á¶ÀåÇö(Á¶¼±ÀÇ´ë, Àü³²ÀÇ´ë, ¸ñÆ÷Çѱ¹º´¿ø, ¼øõ¼º°¡·Ñ·Îº´¿ø) 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 12:20~13:10 Luncheon Session  °í¿µ¿±, ¿À¼®±Ô(Á¶¼±ÀÇ´ë, ¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 12:20~12:35 CV outcomes with evolocumab: who are the target patients?  ±è¿ø(°æÈñÀÇ´ë) 
±³À°½Ã°£ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 12:35~12:50 Why is PCSK9-I needed for patients with AMI: Insight the KAMIR data  ±è¿ëö(Àü³²ÀÇ´ë) 
Åä·Ð 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 12:50~13:10 ÅäÀÇ  ¹Ú±ÙÈ£, ¾È¿µ±Ù, À±°æÈ£, ÀÌ»ó·Ï, Ȳ¼±È£(Á¶¼±ÀÇ´ë, Àü³²ÀÇ´ë, ¿ø±¤ÀÇ´ë, ÀüºÏÀÇ´ë, ±¤ÁÖº¸Èƺ´¿ø) 
±âŸ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 13:10~13:30 ÃÑȸ  È£³²¼øȯ±âÇÐȸ() 
±âŸ 12-08 ¿©¼öº£³×Ä¡¾ÆÈ£ÅÚ ÄÁº¥¼ÇȦ 13:30~13:40 ¿ì¼ö±¸¿¬Æ÷½ºÅÍ»ó ½Ã»ó ¹× Æóȸ»ç  Á¤¸íÈ£(È£³²¼øȯ±âÇÐȸ ÀÌ»çÀå) 
  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­Á : 2024-03-09

±³À°ÀÏÀÚ : 2024-03-09 ±³À°Àå¼Ò : (¿Â¶óÀÎ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ½Å¼ººóÇ÷¿¬

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,657 , ´ñ±Û¼ö : 0

[¼­¿ï] Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialysis Vascular Access) : 2024-03-31

±³À°ÀÏÀÚ : 2024-03-31 ±³À°Àå¼Ò : °¡Å縯ÀÇ´ë ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ ±³À°ÁÖÁ¦ : Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialy

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,712 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-16

±³À°ÀÏÀÚ : 2024-03-16 ±³À°Àå¼Ò : ÇØ¿î´ë¹éº´¿ø 5Ãþ ´ë°­´ç ±³À°ÁÖÁ¦ : 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ»ê¿ï

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,708 , ´ñ±Û¼ö : 0

[¼­¿ï] ¼¼ºê¶õ½ºº´¿ø 2018 ¼¼¸ñȸ Çмú´ëȸ : 2018-11-10

±³À°ÀÏÀÚ : 2018-11-10 ±³À°Àå¼Ò : °­³² ¼¼ºê¶õ½ºº´¿ø ´ë°­´ç ±³À°ÁÖÁ¦ : 2018 ¼¼¸ñȸ Çмú´ëȸ ÁÖÃÖ±â°ü : ¼¼ºê¶õ½ºº´¿ø ½ÃÇà±â°ü(ÁöºÎ/°ú) : ¾È°ú ´ã´çÀÚ : ¹Ú

Ãßõ¼ö : 0 , Á¶È¸¼ö : 6,392 , ´ñ±Û¼ö : 0

[¼­¿ï] ´ëÇÑÁ¶Çöº´ÇÐȸ Treatment and management of symptoms and physical health in schizophrenia : 2024-04-2..

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü ±³À°ÁÖÁ¦ : Treatment and management of symptoms and physical health i

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,398 , ´ñ±Û¼ö : 0